Encouragingly, SY-5007 demonstrated promising clinical activity, with significant anti-tumor efficacy observed in both treatment-naïve and previously treated patients across various RET-altered tumor types, including NSCLC, PTC, and MTC, irrespective of fusion partners and prior MKI exposure. This evidence concerns the gene RET and non-small cell lung carcinoma.